Patients with inflammatory diseases such as rheumatoid arthritis or psoriasis have a higher risk of developing Alzheimer’s disease, which can be reduced by treatment with tumor necrosis factor (TNF) inhibitors. That finding, “Tumor Necrosis Factor (TNF) Blocking Agents Reduce Risk for Alzheimer’s Disease in Patients with Rheumatoid Arthritis and Psoriasis,” was published in the journal medRxiv and presented in a scientific poster, during the 12th Clinical Trials on Alzheimer’s Disease Meeting (CTAD), held in San Diego, California, in December. Alzheimer’s progression involves inflammatory changes in the brain, which are thought to be driven, at least in part, by the overproduction of pro-inflammatory molecules like TNF.
Read more from Alzheimers News Today.
